J.P. Morgan reports that over the weekend, Nektar Therapeutics NKTR presented promising Ph2 data for NKTR-102 in second line metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium (SABCS) wherein the objective response rate improved since this summer's topline update (29% from 21%).
As a result, J.P. Morgan is maintaining its OW rating on Nektar Therapeutics, which closed Friday at $14.06.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in